96.3% in New Hampshire. 4 The variance was even greater for the meningococcal conjugate vaccine, with 37.5% of adolescents receiving the vaccine in Arkansas and 94.3% receiving it in Rhode Island. 4 Adherence to the human papillomavirus (HPV) vaccine is even lower, perhaps reflecting social and religious issues interfering with vaccination and leading states to resist making the vaccine mandatory.
In Mississippi, only 12.1% of females (aged 13 to 17 years) have received all 3 doses of the HPV vaccine. 4 Even in Rhode Island, which has one of the highest percentages of child vaccination, less than 60% of females have completed the full course of HPV vaccines. 4 This lack of HPV vaccination exists despite the evidence demonstrating a reduction of cervical and anal cancer associated with the use of the vaccine. 5 With the benefits and adversities of vaccination in mind, the articles in this supplement were developed to assist practicing physicians in improving adolescent vaccination rates. The articles discuss which vaccines should be administered to adolescents and young adults between the ages of 12 and 20 years 6 and what adverse events to expect, with emphasis on the safety of vaccines and the rarity of clinically significant adverse events. 7 In addition, in light of the fact that more 
